Weekly ESG Controversies (June 10~16)

Key takeaways

• Elevation in Customer Welfare Issues:

  • Regulatory non-compliance and health safety issues have propelled customer welfare concerns, particularly with Medytox and Samyang Foods, from 5.66% to 16.85%.

  • The partial legal victory by Medytox over product approval suspension highlights the critical nature of regulatory adherence in ensuring public health safety.

• Focus on Labor Practices and Business Ethics:

  • Samsung Electronics and Ssangbangwool Group have brought labor and ethical issues to the forefront, emphasizing the need for transparent and fair business practices.

  • The emphasis on resolving performance-based compensation disputes and addressing bribery and unethical actions underlines the ongoing challenges in maintaining ethical standards.

• Diversified Risks in Competitive Behavior:

  • Despite a decrease from 24.05% to 15.24%, the landscape of 'Competitive Behavior' risks extended beyond the usual management and intellectual property disputes to include political favors, plagiarism suspicions, technology leaks, and unfair support issues.

• Systematic Risk Management Concerns:

  • The focus on ‘Customer Privacy’ and ‘Data Security’ has led to an increase in ‘Systematic Risk Management’ attention, spotlighting Kakao and NAVER with a rise from 5.83% to 7.84%.

1. Customer Welfare (16.85%)

• MEDY-TOX achieved partial success in the appellate court against the cancellation of their product approval and the order to cease manufacturing and sales.

• Both MEDY-TOX and SAMYANG FOODS have initiated product recalls due to violations of the Pharmaceutical Affairs Law and health safety issues.

2. Business Ethics (15.5%)

• Ssangbangwool Group faces ongoing controversies over bribery and illicit transfers to North Korea, spotlighting long-term ethical concerns.

• Breach of trust and embezzlement allegations persist, with companies like INNOSYS and OTTOGI coming under scrutiny, highlighting widespread issues in business ethics.

3. Competitive Behavior(15.24%)

• A range of risks including management disputes, political favors, plagiarism, technology leaks, and unfair support are concurrently emerging, indicating diverse competitive challenges.

4. Systemic Risk Management (7.84%)

• Systematic risks are rising, particularly with concerns over personal information protection and data security.

• SK SECURITIES continues to garner attention for issues related to credit rating downgrades, highlighting financial systemic risks.

  
  

5. Labor Practices (7.45%)

• The issue continues to be prominent, with NAMYANG DAIRY PRODUCTS’ controversy over the former chairman's severance package marking a significant 22.51% attention rise.

• In light of performance bonus disputes, BGF RETAIL sees the establishment of the convenience store industry's first labor union, signaling growing worker activism.

  
  

This week's observations on ESG risks vividly illustrate the vast and intricate array of dangers that industries and individual companies might encounter. For instance, the protracted litigation faced by Medytox over a specific issue and the unforeseen new risks like political entanglement allegations against SK Group showcase both the enduring and the emerging challenges in today's business landscape. Furthermore, recent concerns around ‘personal information protection’ and ‘data security’ transitioning into broader ‘systematic risk management’ issues highlight how certain risks can evolve into others, suggesting a complex interplay of risk factors.

In response, it is crucial for companies not only to swiftly address and mitigate long-standing risks but also to continuously monitor for newly arising or transitioning risks to effectively reduce their exposure. This proactive and comprehensive approach to risk management is essential for maintaining stakeholder trust and ensuring sustainable business operations in an increasingly unpredictable and interconnected world.

Disclaimer: This content was made with the help of AI. It may contain errors or inaccuracies, and should not be relied upon as a substitute for professional advice. The information contained in this article is not investment advice. FairLabs does not endorse or recommend any investments and assumes no liability for any consequence relating directly or indirectly to any action or inaction taken based on the information contained in this article.

All rights reserved. © FairLabs 2024